Clinical trials
Biliary Tract Carcinoma clinical trials
Below are recruiting biliary tract carcinoma clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06529718RecruitingPhase 2
Ivonescimab vs FOLFOX for advanced bile duct cancer
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
AmiensAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT06168292Recruiting
Combined treatment for bile duct cancer
This trial is testing a new approach for people with bile duct cancer that cannot be removed by surgery. It combines a procedure that uses heat to destroy cancer cells inside the bile duct with standard radiation therapy.
Goyang-si, OtherAges 20 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05520788Recruiting
Genetic test-guided treatment for advanced bile and liver cancers
This study looks at using a genetic test (next-generation sequencing) to find cancer gene changes in stage IV hepatobiliary cancer. If there is a matching approved medicine, the study follows how well the “right drug for the right mutation” helps patients receiving palliative care.
Wuhan, HubeiAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT06434597RecruitingPhase 2
Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
BeijingAges 18 years+ - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT04645160RecruitingPhase 1/Phase 2
Tivozanib for bile duct and gallbladder cancers after chemotherapy
This Phase 1/2 trial tests tivozanib (a targeted anti-cancer drug) in people with bile duct or gallbladder cancer that cannot be removed by surgery and has already been treated with first-line chemotherapy. The study looks at how well the drug works and how safe it is in this setting.
Bethesda, MarylandAges 18 years+ - NCT05222971RecruitingPhase 2
Olaparib, with or without immunotherapy, for DNA-repair biliary cancer
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
SeoulAges 19 years+ - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75 - NCT07530445RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced biliary tract cancer
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
GuangzhouAges 18–70 - NCT05749900RecruitingPhase 1/Phase 2
First-line antibody, chemo, and immunotherapy for HER2 bile duct cancer
This trial studies a combination of trastuzumab (an antibody), gemcitabine and cisplatin (chemo), plus nivolumab (immunotherapy) as the first treatment for advanced HER2-positive biliary tract cancer. It may help shrink tumors and improve outcomes by targeting HER2 and boosting the immune system.
SeoulAges 19 years+ - NCT05615818RecruitingPhase 3
Study of targeted drug choices for advanced bile duct cancers
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
BrusselsAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT06274879RecruitingPhase 2
Radiofrequency ablation for bile duct cancer
This trial tests a procedure that uses heat (radiofrequency ablation) to treat bile duct cancer that can't be removed by surgery. If you have this type of cancer and are starting standard treatment, this study wants to see if adding this heat treatment is safe and might help.
BernAges 18 years+ - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT04907643Recruiting
Virtual reality program to reduce stomach-cancer pain
This trial tests whether virtual reality (VR) can improve pain and other day-to-day symptoms in people with certain gastrointestinal cancers. You’d use VR for pain relief while researchers measure how you’re feeling.
Los Angeles, CaliforniaAges 18–99 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract carcinoma?
- Yes. Clin2 currently lists 87 recruiting biliary tract carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.